A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
← catalyst calendarNCT05100862 · readout ≤ 712 d
Sponsored by BeOne Medicines (industry) · ONC — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
799actual
Sites
266
Countries
Argentina, Australia, Austria +25
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-03-10 | actual | When the study began enrolling |
| Primary completion | Jul 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2021-10-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Relapsed/Refractory Follicular Lymphoma
- Marginal Zone Lymphoma
Interventions
- Drug: Zanubrutinib — also filed as BGB-3111, Brukinsa
- Drug: Rituximab — also filed as Rituxan, MabThera, Ruxience, Truxima
- Drug: Lenalidomide — also filed as Revlimid
- Drug: Obinutuzumab
Primary outcome
what the primary-completion date above is the date OFProgression-free Survival As Determined By A Blinded Independent Review Committee (BIRC)
measured Approximately 78 months
Permalink · ONC's whole pipeline · Catalyst calendar · Every registered study · What changed